TRIM25
Basic information
Region (hg38): 17:56836387-56914080
Previous symbols: [ "ZNF147" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (5 variants)
- Immunoglobulin-mediated membranoproliferative glomerulonephritis (4 variants)
- Atypical hemolytic-uremic syndrome (3 variants)
- AHUS, SUSCEPTIBILITY TO, 7 (1 variants)
- Nephrotic syndrome (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the TRIM25 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 3 | |||||
missense | 41 | 47 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 3 | 3 | ||||
non coding | 51 | 57 | 24 | 147 | ||
Total | 7 | 8 | 92 | 63 | 27 |
Highest pathogenic variant AF is 0.000151
Variants in TRIM25
This is a list of pathogenic ClinVar variants found in the TRIM25 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
17-56843797-C-CA | Benign (May 12, 2021) | |||
17-56843797-C-CAAAAA | Benign (Aug 20, 2019) | |||
17-56843797-C-CAAAAAA | Benign (Dec 29, 2019) | |||
17-56843961-G-A | Benign (Nov 11, 2018) | |||
17-56844007-TC-T | Likely benign (Aug 19, 2022) | |||
17-56844014-C-G | Likely benign (Nov 04, 2024) | |||
17-56844014-C-T | Likely benign (Sep 23, 2022) | |||
17-56844016-C-T | Likely benign (Jan 06, 2025) | |||
17-56844017-A-G | Immunoglobulin-mediated membranoproliferative glomerulonephritis | Likely pathogenic (Apr 04, 2024) | ||
17-56844023-A-AT | Atypical hemolytic-uremic syndrome | Likely pathogenic (-) | ||
17-56844034-G-A | Likely benign (Oct 29, 2023) | |||
17-56844039-C-CA | Hemolytic uremic syndrome, atypical, susceptibility to, 7 • Atypical hemolytic-uremic syndrome | Likely pathogenic; risk factor (May 01, 2013) | ||
17-56844057-T-C | Uncertain significance (May 29, 2024) | |||
17-56844058-G-A | Uncertain significance (Sep 06, 2022) | |||
17-56844073-G-A | Likely benign (Sep 16, 2024) | |||
17-56844085-T-G | Immunoglobulin-mediated membranoproliferative glomerulonephritis | Uncertain significance (-) | ||
17-56844095-G-T | Pathogenic (Jun 23, 2024) | |||
17-56844112-C-T | Likely benign (Feb 11, 2024) | |||
17-56844114-T-A | Uncertain significance (Apr 23, 2022) | |||
17-56844115-TCCACCAAGTTATTTAACATCCA-T | Pathogenic (Apr 23, 2022) | |||
17-56844116-C-A | Inborn genetic diseases | Uncertain significance (Apr 27, 2022) | ||
17-56844122-A-G | Uncertain significance (Jun 20, 2023) | |||
17-56844133-A-C | not specified • Immunoglobulin-mediated membranoproliferative glomerulonephritis | Benign (Feb 03, 2025) | ||
17-56844133-A-T | Likely benign (Jul 20, 2022) | |||
17-56844137-A-G | Uncertain significance (Nov 07, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
TRIM25 | protein_coding | protein_coding | ENST00000316881 | 9 | 26130 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00412 | 0.996 | 125731 | 0 | 17 | 125748 | 0.0000676 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.859 | 303 | 348 | 0.870 | 0.0000189 | 4099 |
Missense in Polyphen | 84 | 111.81 | 0.75126 | 1428 | ||
Synonymous | 0.603 | 144 | 154 | 0.938 | 0.00000901 | 1224 |
Loss of Function | 3.16 | 9 | 26.6 | 0.339 | 0.00000122 | 329 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000210 | 0.000210 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000109 | 0.000109 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000623 | 0.0000615 |
Middle Eastern | 0.000109 | 0.000109 |
South Asian | 0.0000777 | 0.0000653 |
Other | 0.000177 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Functions as a ubiquitin E3 ligase and as an ISG15 E3 ligase. Involved in innate immune defense against viruses by mediating ubiquitination of DDX58. Mediates 'Lys-63'-linked polyubiquitination of the DDX58 N-terminal CARD-like region which is crucial for triggering the cytosolic signal transduction that leads to the production of interferons in response to viral infection. Promotes ISGylation of 14-3-3 sigma (SFN), an adapter protein implicated in the regulation of a large spectrum signaling pathway. Mediates estrogen action in various target organs. Mediates the ubiquitination and subsequent proteasomal degradation of ZFHX3 (PubMed:22452784). {ECO:0000269|PubMed:16352599, ECO:0000269|PubMed:17069755, ECO:0000269|PubMed:17392790, ECO:0000269|PubMed:22452784}.;
- Pathway
- Influenza A - Homo sapiens (human);NF-kappa B signaling pathway - Homo sapiens (human);RIG-I-like receptor signaling pathway - Homo sapiens (human);RIG-I-like Receptor Signaling;DNA Repair;estrogen responsive protein efp controls cell cycle and breast tumors growth;Cytokine Signaling in Immune system;NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10;Post-translational protein modification;TRAF6 mediated IRF7 activation;TRAF6 mediated NF-kB activation;DDX58/IFIH1-mediated induction of interferon-alpha/beta;Metabolism of proteins;TCR;Innate Immune System;Immune System;TRAF3-dependent IRF activation pathway;Negative regulators of DDX58/IFIH1 signaling;Ovarian tumor domain proteases;Deubiquitination;Interferon gamma signaling;Termination of translesion DNA synthesis;Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template;DNA Damage Bypass;ISG15 antiviral mechanism;Antiviral mechanism by IFN-stimulated genes;Interferon Signaling
(Consensus)
Recessive Scores
- pRec
- 0.170
Intolerance Scores
- loftool
- 0.520
- rvis_EVS
- -0.22
- rvis_percentile_EVS
- 37.54
Haploinsufficiency Scores
- pHI
- 0.0876
- hipred
- Y
- hipred_score
- 0.686
- ghis
- 0.518
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.833
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Trim25
- Phenotype
- immune system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype;
Gene ontology
- Biological process
- ubiquitin-dependent protein catabolic process;protein monoubiquitination;viral process;translesion synthesis;ubiquitin-dependent ERAD pathway;negative regulation of type I interferon production;response to vitamin D;positive regulation of I-kappaB kinase/NF-kappaB signaling;response to estrogen;innate immune response;regulation of viral entry into host cell;negative regulation of viral entry into host cell;positive regulation of DNA-binding transcription factor activity;positive regulation of NF-kappaB transcription factor activity;defense response to virus;interferon-gamma-mediated signaling pathway;regulation of viral release from host cell;negative regulation of viral release from host cell;cellular response to leukemia inhibitory factor
- Cellular component
- nucleoplasm;cytosol;nuclear body
- Molecular function
- RNA binding;ubiquitin-protein transferase activity;protein binding;zinc ion binding;ligase activity;cadherin binding;ubiquitin protein ligase activity